Moreover, tumors can develop resistance to anti-angiogenic agents over time. This is often due to the tumor's ability to activate alternative pathways for angiogenesis or adapt to a low-oxygen environment. As a result, ongoing research is focused on combination therapies and identifying biomarkers to predict response and resistance.
